Eric van Exel
GGZinGeest/Amsterdam UMCAmsterdam, Netherlands
381 RESULTS
GGZinGeest/Amsterdam UMCAmsterdam, Netherlands
THERAPEUTICS Denali Therapeutics Inc. Small Molecule Other In February 2020, Denali began a Phase 1 trial testing single and multiple ascending oral doses of DNL343 in 88 healthy adults. The primary outcomes are safety and plasma pharmacokinetics measured up to 20 day
COMMENT BrightFocus is mourning the loss of Dr. Peter Davies. We are especially proud and grateful to have had him serve as a member of our Alzheimer’s Disease Research Scientific Review Committee from 1989 to 2000, and co-chair for six of these years. His leader
Kobe University Graduate School of MedicineKobe, Japan
PAPER Freitas CS, Pinheiro MG, Fonte EJ, Hazin AN, Smid J, Barbosa BJ
PAPER Lo Monaco MR, Di Tella S, Anzuino I, Ciccarelli N, Silveri MC